SEATTLE, March 21, 2025--Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart ...

Latest independent research from Spherix Global Insights highlights growing urgency to treat PNH with complement or factor inhibitors, shifting physician preferences, and the impact of biosimilar ...

It’s important to be a proactive PNH patient. You’ll want to know how to how to find a doctor and manage your treatment.

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).

(RTTNews) - Swiss drug maker Novartis AG (NVS) announced Thursday that Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve ...

The dominance of the C5 inhibitors Ultomiris and Soliris in PNH was one of the reasons AstraZeneca’s $39 billion acquisition of the rare-disease-focused Alexion looked like such a good move in 2020.

PNH is a rare, chronic, and life-threatening blood disease in which uncontrolled complement activation leads to the destruction of red blood cells through intravascular hemolysis and ...

Novartis has reported positive outcomes from the multi-centre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan) in adults with paroxysmal nocturnal haemoglobinuria (PNH). These findings ...

NovelMed’s Phase II Data in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Shows Best-in-Class Efficacy as Monotherapy ...

The global market size for PNH is reported at $3.8 billion dollars in 2023 and projected at over $11.7 billion dollars in 2034. Currently, ...